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Abstract
Rationale The specific role of neuromodulator systems in reg-
ulating rapid fluctuations of attention is still poorly
understood.
Objectives In this study, we examined the effects of clonidine
and scopolamine on multiple target detection in a rapid serial
visual presentation task to assess the role of the central norad-
renergic and cholinergic systems in temporal attention.
Method Eighteen healthy volunteers took part in a crossover
double-dummy study in which they received clonidine (150/
175 μg), scopolamine (1.2 mg), and placebo by mouth in
counterbalanced order. A dual-target attentional blink task
was administered at 120 min after scopolamine intake and
180 min after clonidine intake. The electroencephalogram
was measured during task performance.
Results Clonidine and scopolamine both impaired detection
of the first target (T1). For clonidine, this impairment was
accompanied by decreased amplitudes of the P2 and P3 com-
ponents of the event-related potential. The drugs did not im-
pair second-target (T2) detection, except if T2 was presented
immediately after T1. The attentional blink for T2 was not
affected, in line with a previous study that found no effect of
clonidine on the attentional blink.
Conclusions These and other results suggest that clonidine
and scopolamine may impair temporal attention through a
decrease in tonic alertness and that this decrease in alertness
can be temporarily compensated by a phasic alerting response
to a salient stimulus. The comparable behavioral effects of
clonidine and scopolamine are consistent with animal studies
indicating close interactions between the noradrenergic and
cholinergic neuromodulator systems.
Keywords Attentional blink . Rapid serial visual
presentation . Temporal attention . Noradrenaline .
Acetylcholine
Introduction
Temporal attention—the dynamic changes in attention on a
fast timescale—is widely studied because it is crucial for or-
ganisms to be able to prioritize and accurately identify incom-
ing information, for example, to make successful decisions. In
recent years, the neuromodulatory basis of temporal attention
has attracted considerable scientific interest. One theory re-
lates temporal attention to the noradrenergic neuromodulator
system. This theory is founded on the idea that the release of
noradrenaline by the locus coeruleus (LC) adjusts the gain of
post-synaptic neurons, thereby modulating these neurons’
responsivity (Servan-Schreiber et al. (1990). The LC has been
demonstrated to fire phasically following the presentation of
task-relevant or salient stimuli (Aston-Jones et al. 2000), and
these phasic bursts are temporally closely related to behavioral
responses (Bouret and Sara 2004). These findings suggest that
the phasic LC response acts as a temporal attention filter that
selectively facilitates the processing of motivationally
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significantly stimuli (Aston-Jones and Cohen 2005;
Nieuwenhuis et al. 2005a).
Rapid changes in temporal attention are commonly studied
with the attentional blink task, in which participants have to
identify two targets that are embedded in a rapid serial visual
stream (RSVP) of distractor stimuli. Participants are usually
able to accurately identify the first of those targets (T1). The
crucial finding in this task is that when the second target (T2)
follows the first target within 200–400 ms, participants are
often unable to report T2 accurately (Raymond et al. 1992;
Chun and Potter 1995). This phenomenon is referred to as the
attentional blink.
Nieuwenhuis and colleagues have proposed a theory in
which the attentional blink reflects the temporal dynamics of
the noradrenergic system (Nieuwenhuis et al. 2005b; see also
Warren et al. 2009). This theory assumes that identification of
T1 is associated with a transient burst of arousal and concom-
itant phasic firing of the LC. Following this T1-related phasic
burst, LC neurons enter a refractory period of reduced firing.
During this period, no noradrenaline-mediated facilitation of
stimulus processing can occur. The characteristic attentional
blink window of 200–400 ms corresponds to the duration of
this refractory period, which would explain why participants
often fail to detect T2 if it is presented within this time window.
This theory also accounts for the phenomenon of lag-1 sparing
(Raymond et al. 1992; Hommel and Akyürek 2005):
Participants generally do detect T2 if it directly follows T1
(i.e., at Blag 1^). When there is such a close temporal proximity
of T1 and T2, detection of T2 is proposed to benefit from the
phasic noradrenaline burst elicited by T1 (Usher et al. 1999).
There is direct empirical evidence for the involvement of
the noradrenergic system in target detection under rapid serial
visual presentation conditions. For example, antagonization of
noradrenergic β receptors by propranolol led to impaired T2
identification in humans (de Martino et al. 2008).
Furthermore, patients with dopamine-β-hydroxylase deficien-
cy, a rare genetic syndrome characterized by the complete
absence of noradrenaline, were shown to have a larger atten-
tional blink than healthy controls, and this impairment was
restored by treatment with a synthetic precursor of noradren-
aline (Jepma et al. 2011). However, when Nieuwenhuis et al.
(2007) used the noradrenergic α2 agonist clonidine to attenu-
ate noradrenergic baseline activity, they did not find a reliable
decrease in T2 identification accuracy, a finding that seems at
odds with the theory of Nieuwenhuis et al. (2005b).
The goal of the present experiment was to replicate the
study by Nieuwenhuis et al. (2007) but with two improve-
ments: a crossover design instead of a between-subject design
to increase statistical power and an increased dose of clonidine
to induce a more pronounced attenuation of the noradrenergic
system. Furthermore, we recorded the electroencephalogram
(EEG) to acquire more insight into the electrophysiological
correlates of treatment effects on RSVP performance.
We tested 18 healthy adult participants in a double-blind
placebo-controlled randomized crossover design. Participants
received, in different test sessions, a single dose of clonidine,
scopolamine, and placebo. Clonidine is a centrally acting α2
agonist that attenuates baseline noradrenergic activity by ago-
nizing pre-synaptic α2 receptors and decreases the amplitude
of the human P3 component, a putative electrophysiological
correlate of phasic noradrenaline release (Nieuwenhuis et al.
2005a; Pineda et al. 1989). Due to its antihypertensive prop-
erties, the main indication of this drug is hypertension, but it is
also indicated to reduce menopausal hot flashes and as an
adjuvant in opiate withdrawal treatment. Its most common
side effects are dizziness, sedation, orthostatic hypotension,
and dry mouth. If the attentional blink is mediated by a phasic
noradrenergic burst following presentation of T1 and cloni-
dine decreases this phasic burst, then clonidine may be expect-
ed to reduce the attentional blink. Notably, previous event-
related potential (ERP) studies have associated the attentional
blink with a larger or a delayed T1-elicited P3 (Martens et al.
2006; Sergent et al. 2005; Slagter et al. 2007). We were thus
specifically interested in possible effects of clonidine on the
T1-elicited P3.
The involvement of the cholinergic system in temporal
attention has been investigated less extensively than that of
noradrenaline. Previous empirical work has focused on the
nicotinic cholinergic system and has not studied RSVP per-
formance but other temporal attention tasks like temporal cu-
ing (e.g., Beane and Marrocco 2004; Stewart et al. 2001).
Therefore, we also administered the muscarinic antagonist
scopolamine, a drug with a sedation profile comparable to that
of clonidine. Scopolamine has pronounced antiemetic proper-
ties, and its main indications are therefore (post-operative)
nausea and motion sickness, but it is also indicated to treat
gastrointestinal spasms. Its main side effects are dry mouth,
bradycardia, and mydriasis. The use of scopolamine allowed
us to gain insight into the role of the cholinergic muscarinic
system in temporal attention and to test whether any treatment
effects are specific to the noradrenergic system.
Methods and materials
Participants
Eighteen healthy young adults (15 women), aged 18–26 years
(mean age 21 years), drafted through Leiden University’s par-
ticipant recruitment system, took part in three 4.5-h experi-
mental sessions in return for €140. Only participants with a
systolic blood pressure above 100 mmHg, a diastolic blood
pressure above 70mmHg, and a heart frequency over 65 beats
per minute in rest were included in the study (cf. Nieuwenhuis
et al. 2007). All participants underwent a medical screening
which included a routine physical examination prior to being
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included in the experiment: Only healthy individuals without
a history of neurological or psychiatric disorders were allowed
to participate. Participants took no prescribed medication and
did not smoke; participants were instructed to abstain from
using recreational drugs, caffeine, or alcohol 15 h prior to
the study. Female participants were asked whether they were
pregnant or thought they might be pregnant to preclude preg-
nant females from participating. Participants received a single
oral dose of clonidine, a single oral dose of scopolamine
(1.2 mg), and a placebo in a randomized, double-blind,
counterbalanced double-dummy crossover design. The first
11 participants received a clonidine dose of 175 μg. As the
11th participant showed an unexpected large drop in blood
pressure of 35 mmHg systolic, but without clinical conse-
quences, 60 min after the ingestion of clonidine 175 μg (blind
was broken by the supervising physician), we decided to re-
duce the dose of clonidine to 150 μg for the final seven par-
ticipants. Preliminary repeated measures ANOVAs with dose
as between-subject factor revealed no reliable main effect of
dose or interactions including this factor, so in the analyses
reported below, the 18 participants are pooled. Clonidine, sco-
polamine, and placebo were administered during three sepa-
rate test sessions, spaced 1 week apart. The study was ap-
proved by the medical ethics committee of the Leiden
University Medical Center. Written informed consent was ob-
tained from all participants prior to inclusion in the study.
Task
Participants performed an attentional blink task. Each trial
started with a 500-ms fixation point (black plus sign on light
gray background, visual angle 0.6°×0.6°), followed by a 2-s
blank, after which a RSVP stream of 22 uppercase letters was
presented centrally (visual angle of each letter approximately
0.7°×0.7°) on an IIyama Vision Master CRT monitor with a
refresh rate of 100 Hz, using E-Prime 2.0 (Psychology
Software Tools, Sharpsburg, PA). Each letter was randomly
drawn without replacement from the alphabet and presented
for 70 ms, followed by a blank of 30 ms. The letters I, O, Q,
and Swere left out, as they resemble digits too much. On each
trial, two letters were replaced by digits (range 2–9, chosen
randomly without replacement): targets 1 and 2 (T1 and T2).
T2 was presented three to six temporal positions from the end
of the stream. The temporal distance between T1 and T2 was
either one (12.5 % of trials), two (37.5 % of trials), three
(37.5 % of trials), or seven items (12.5 % of trials), corre-
sponding to lags of 100, 200, 300, and 700 ms. Immediately
after the end of the RSVP stream, participants were asked to
identify T1 and T2 by typing them, in order, on a standard
keyboard. The task consisted of six blocks of 40 trials each
and was preceded by a practice block of 12 trials, in which
feedback on the participants’ performance was given on every
trial (e.g., a display of B+ −^ indicated that a participant had
entered T1 correctly and T2 incorrectly).
Procedure
Each participant was tested at approximately the same time of
day. During every test session, participants received a capsule
of clonidine or placebo at 09.35 AM and a capsule of scopol-
amine or placebo at 10.35 AM. The different kinetic profiles
of clonidine and scopolamine necessitated administrations at
different times prior to testing. This double-dummy design
resulted in one clonidine session (i.e., clonidine verum plus
scopolamine placebo), one scopolamine session (clonidine
placebo plus scopolamine verum), and one placebo session
(clonidine plus scopolamine placebos). To eliminate any pos-
sible confound of drug order, we stratified this factor by dis-
tributing the six possible drug orders evenly across
participants.
The procedure in each test session is illustrated in Fig. 1. At
the start of each session (t=−20 min), a peripheral intravenous
cannula was placed and connected to an intravenous 0.9 %
NaCl (saline) drip to be able to increase blood pressure
through volume expansion and to have an entryway to admin-
ister escape medication in the case of a severe drop in tension
and/or heart frequency. Furthermore, three cardio electrodes
were applied to the participant’s chest and connected to an
electrocardiography (ECG) monitor. To measure the sedative,
alertness-reducing properties of clonidine and scopolamine,
Fig. 1 Timeline of the procedure
in each test session. Connector
lines indicate the start of an event.
Each cognitive task lasted
approximately 30 min.
Participants’ blood pressure and
heart rate were measured at
baseline (t=−20) and then every
15 min, starting at t=0. Results
from the other cognitive tasks are
reported elsewhere (asterisk)
(Brown et al. 2015a, b). SRT
simple reaction time task
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we administered a 40-trial simple reaction time task upon a
participant’s arrival in the lab, as well as right before and after
the participant performed the attentional blink task.
Participants had to respond as quickly as possible whenever
a white circle appeared on the computer screen. Stimulus on-
set asynchrony was jittered between 500 and 1250 ms, with a
mean of 1000 ms; this task lasted less than 2 min.
At t=0 min, participants ingested a microcrystalline
cellulose-filled capsule with either clonidine or placebo.
Clonidine has well-established antihypertensive properties:
Therefore, blood pressure and heart rate were monitored four
times an hour from t=0 onwards for participant safety with an
Omron M10-IT automatic sphygmomanometer. At t=60 min,
participants ingested a microcrystalline cellulose-filled cap-
sule with either scopolamine or placebo.
At t=180, participants performed the attentional blink task
which lasted approximately 30 min; during the 90 min prior to
this time point, participants performed three unrelated cogni-
tive tasks (Brown et al. 2015a, b). Participant fitness was
checked at t=240, and participants were sent home via public
transportation if their blood pressure and heart rate were close
to the values measured at t=−20; if their blood pressure and
heart rate had not returned to normal yet, they were kept for
further observation. At the end of the third test session, par-
ticipants received their financial compensation.
EEG recording and analyses
We recorded EEG from 64 Ag/AgCl scalp electrodes and
from the left and right mastoids. We measured the horizontal
and vertical electro-oculogram (EOG) using bipolar record-
ings from electrodes placed approximately 1 cm lateral of
the outer canthi of the two eyes and from electrodes placed
approximately 1 cm above and below the participant’s right
eye. The EEG signal was pre-amplified at the electrode to
improve the signal-to-noise ratio and amplified with a gain
of 16× by a BioSemi ActiveTwo system (BioSemi B.V.,
Amsterdam). The data were digitized at 24-bit resolution with
a sampling rate of 512 Hz using a low-pass fifth-order sinc
filter with a half-power cutoff of 102.4 Hz. Each active elec-
trode was measured online with respect to a common mode
sense (CMS) active electrode producing a monopolar (non-
differential) channel and was referenced offline to the average
of the left and right mastoids. Data were high-pass filtered at
0.1 Hz and low-pass filtered at 30 Hz. Ocular and eyeblink
artifacts were corrected using the method of Gratton et al.
(1983). Epochs with other artifacts (a gradient greater than
30 μV, slow drifts [>300 μV/200 ms], and low activity
[<0.50 μV/100 ms]) were discarded (placebo 1.2 %, clonidine
1.3 %, and scopolamine 2.5 %). Data were epoched from
−100 to 600 ms relative to the onset of T1 and then averaged.
A baseline, computed as the average signal activity across the
100 ms prior to T1, was subtracted for each ERP. Data pre-
processing was performed in Brain Vision Analyzer 2 (Brain
Products, Gilching, Germany).
As the active compounds only reliably influenced T1 ac-
curacy (regardless of lag) and given previous studies linking
the T1-evoked P3 to the attentional blink (e.g., Martens et al.
2006; Sergent et al. 2005; Slagter et al. 2007), we focused our
electrophysiological analyses on T1-evoked potentials. Using
MATLAB (TheMathWorks, Natick, MA), we analyzed the ERP
elicited by T1 with a sliding-window approach to examine
whether clonidine and scopolamine differed from placebo,
focusing in particular on electrodes Cz, CPz, and Pz, where
the P3 was largest in amplitude. We collapsed T1-locked
ERPs across lags, split the ERPs for each treatment and each
participant into 19.5-ms windows, starting at t=0 (i.e., 0–19.5,
21.5–39 ms, etc.), and then, for each window separately, sub-
mitted the average amplitudes to paired sample t tests with
treatment (clonidine or scopolamine vs. placebo) as indepen-
dent variable.
Results
Greenhouse-Geisser corrections were applied whenever the
assumption of sphericity was violated; in such cases, uncor-
rected degrees of freedom are reported.
Physiological and alertness data
Figure 2a shows that, as expected, clonidine lowered systolic
(mean tension 101 mmHg) and diastolic (65 mmHg) blood
pressure relative to placebo (mean tension 112/73 mmHg),
also during performance of the attentional blink task (t=
180–210), all t17>4.5, ps<.0005. The difference in systolic
and diastolic blood pressure between placebo and scopol-
amine was not significant. Figure 2b shows that scopolamine
(61/min), as expected, lowered heart frequency relative to pla-
cebo (71/min) and clonidine (69/min), also during perfor-
mance of the attentional blink task, all t17>3.3, ps<.004.
To test the subjects’ alertness, we administered a simple
reaction time task at baseline (arrival of participant), right
before, and right after performing the attentional blink task.
As expected, the baseline measurements did not differ be-
tween treatments, F(2, 34)<1, p=.95. To examine the effect
of treatment on pre- and post-test measurements (Fig. 2c), we
subtracted the baseline values from each of these measure-
ments and submitted the difference scores to a 3 (treat-
ment)×2 (time point) repeated measures ANOVA. This anal-
ysis yielded a main effect of treatment, F(2, 34)=4.8, p=.019,
partial η2=.22, but no interaction between treatment and time
point, F(2, 34)=1.6, p=.22. Pairwise comparisons indicated
that clonidine and scopolamine reliably slowed down simple
reaction time compared to placebo during both the pre-test
(t17=2.1, p=.05 and t17=2.3, p=.04, respectively) and the
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post-test (t17=3.1, p=.006 and t17=3.3, p=.005, respectively).
The differences between clonidine and scopolamine were not
significant.
Behavioral data
Trials on which T1 and T2 were accurately identified but in
the wrong order were treated as correct (cf. Nieuwenhuis et al.
2007). Thus, the probability of guessing T1 and T2 correctly
was 3.6 %.
Figure 3 (left panel) shows average T1 accuracy as a func-
tion of treatment and lag. The main effect of treatment was
significant, F(2, 34)=4.4, p=.02, partial η2=.21. Both cloni-
dine (79.3 %, t17=2.5, p=.02) and scopolamine (79.4 %, t17=
2.4, p=.03) decreased T1 identification accuracy relative to
placebo (85.6 %). T1 identification accuracy increased with
lag, F(3, 51)=6.6, p=.001, partial η2=.28. Treatment and lag
did not interact, F(6, 102)=0.2, p=.96.
To determine if the two drugs also decreased T2 accuracy,
we examined average T2 accuracy, non-contingent on T1
identification, as a function of treatment and lag (Fig. 3, mid-
dle panel). Treatment did not reliably influence T2 identifica-
tion accuracy, F(2, 34)=1.6, p=.21, partial η2=.09. T2 iden-
tification performance showed the characteristic pattern of
lag-1 sparing, a subsequent decrease of accuracy for lags 2
and 3 (i.e., the attentional blink), and a recovery of perfor-
mance for lag 7, F(3, 51)=12.1, p<.0005, partial η2=.42.
Treatment and lag did not interact (p=.051). We found it re-
markable that the treatment effects for lag 1 were of a similar
magnitude as those on T1 accuracy. Indeed, although there
was no overall effect of treatment, analysis of individual lags
yielded a reliable effect of treatment for lag 1, F(2, 34)=5.8,
p=.007, partial η2=.25, but not for the other three lags (all
ps>.44). Pairwise comparisons for lag 1 revealed that accura-
cy in the clonidine (76.6 %; t17=3.1, p=.007) and scopol-
amine (79.1 %; t17=2.9, p=.009) conditions was lower than
in the placebo condition (87.7 %), indicating that the treatment
effects for T1 extended into lag 1 but not further. There was no
reliable difference in accuracy between the clonidine and sco-
polamine conditions (p=.51).
Figure 3 (right panel) shows the results of a similar T2
analysis but constrained to T1-correct trials, as is common in
attentional blink research. This analysis yielded similar statis-
tical results. Treatment did not reliably influence T2 identifi-
cation accuracy, F<1. There was a main effect of lag, F(3,
51)=18.6, p<.0005, partial η2=.52, but no interaction be-
tween treatment and lag (p=.33). Again, separate analyses of
the four lags yielded a reliable effect of treatment for lag 1
only, F(2, 34)=3.3, p=.05, partial η2=.16. Pairwise compari-
sons for lag 1 revealed that T2 accuracy was lower in the
clonidine (92.3 %, t17=2.3, p=.04) and scopolamine (t17=
2.1, p= .05) conditions than in the placebo condition
(97.5 %). There was no reliable difference in accuracy be-
tween the clonidine and scopolamine conditions (p=.40).
Electrophysiological data
Because clonidine and scopolamine only reliably affected T1
accuracy, we next examined the effects of drugs on T1-evoked
ERPs, separately for T1-correct trials (Fig. 4a) and for all
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Fig. 2 a Blood pressure data for
the three treatments. The shaded
gray area indicates significant
pairwise comparisons between
clonidine and placebo (p<.05). b
Heart frequency for the three




(p<.05). c Results from a simple
reaction time task, administered at
the start of the test session
(baseline) and right before (pre-
test) and after (post-test) partici-
pants performed the attentional
blink task
Psychopharmacology (2016) 233:341–350 345
trials, regardless of T1 accuracy (Fig. 4b). Importantly, as is
evident in Fig. 4, the drug-related waveforms lagged behind
the placebo-related waveform, which poses a problem for our
sliding-window approach, because amplitude differences may
in fact reflect latency differences. To deal with this issue, we
first determined the size of the lag for each drug. To do so, we
performed cross-correlations between the grand average
waveforms for placebo and clonidine and for placebo and
scopolamine (cf. Śmigasiewicz et al. 2014). We then shifted,
sample by sample (in ~2-ms steps), the drug-related waveform
relative to the placebo-related waveform and computed the
cross-correlation across the time interval [0, 500 ms]. The
maximum correlations were obtained by shifting the clonidine
waveform 4 samples (~8 ms) to the left and by shifting the
scopolamine waveform 2 samples (~4 ms) to the left. To cor-
rect for these lags, we next shifted the clonidine- and
scopolamine-related waveforms of each subject by the
corresponding duration. Grand average latency-corrected
waveforms are shown in Fig. 4c, d. All ERP analyses reported
below were based on these latency-corrected waveforms.
First, we examined the ERP waveforms for T1-correct tri-
als. As can be seen in Fig. 4c, the sliding-window approach
led to the identification of one significant time interval for
electrode Cz: 217–273 ms. In this P2 window, clonidine was
associated with a smaller mean amplitude (2.1 μV) than pla-
cebo (3.0 μV), t17=2.9, p=.01. Scopolamine (2.5 μV) did not
differ from placebo, t17=1.1, p=.28.
Second, we examined the ERP waveforms based on all
trials (i.e., regardless of T1 accuracy). The motivation for this
analysis was that we were interested in the neural signatures
associated with the drug-related impairment in T1 perfor-
mance. Because several subjects made too few T1 errors to
compute reliable error-specific ERP waveforms, we examined
ERP waveforms based on all trials as neural signatures most
= = =
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T2|T1 correctFig. 3 T1 identification accuracy
(left panel), T2 identification
accuracy (middle panel), and T2
identification accuracy
(conditional upon T1 correct) as a



































































Fig. 4 T1-locked grand average
ERP waveforms for electrode Cz,
plotted separately for each
treatment. The horizontal black
bars indicate time intervals where
clonidine differed from placebo
(see Methods and materials). Up-
per panels: original waveforms;
lower panels: latency-corrected
waveforms (see Results)
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representative of overall T1 performance. Here, the sliding-
window approach led to the identification of two significant
time intervals for electrode Cz (Fig. 4d): 217–273 ms, corre-
sponding to the P2 component, and 373–430 ms, correspond-
ing to the P3. In the P2 interval, clonidine was again associ-
ated with a smaller mean amplitude (2.1 μV) than placebo
(2.9 μV), t17=3.0, p=.009, replicating the analysis based on
T1-correct trials. In the P3 interval, clonidine was also associ-
ated with a smaller mean amplitude (2.9 μV) than placebo
(3.8 μV), t17=2.9, p=.01. Both the P2 effect and the P3 effect
were also significant for electrode CPz, suggesting a
centroparietal locus of these effects. Examination of lag-
specific T1-evoked ERPs indicated that the P2 and P3 effects
were also present for longer lags, excluding the possibility that
these effects constituted treatment effects on T2-related poten-
tials that confounded the T1-evoked waveforms. Amplitudes
for scopolamine generally lay in between clonidine and pla-
cebo (P2 interval 2.4 μV, P3 interval 3.5 μV) but did not differ
reliably from placebo, both ps>.15.
Thus, relative to placebo, clonidine attenuated the ampli-
tudes of the P2 and P3 components evoked by T1, although
the latter effect was only reliable in the ERP analysis including
correct and incorrect trials. Given that missed targets are typ-
ically associated with decreased P3 amplitudes (e.g., Rolke
et al. 2001; dell’ Acqua et al. 2003), the effect of clonidine
on P3 amplitude must have been driven at least in part by the
increased number of included T1-incorrect trials.
Discussion
In the present research, we investigated the effects of clonidine
and scopolamine on multiple target detection in an RSVP
context. In line with Nieuwenhuis et al. (2007), we found no
effect of treatment on the attentional blink for T2. In contrast,
we found that both clonidine and scopolamine impaired T1
accuracy. For clonidine, this effect was accompanied by a
significant reduction in T1-evoked P2 and P3 amplitude.
The current study replicated Nieuwenhuis et al. (2007) with
two design improvements: a crossover design instead of a
between-subject design and a higher dose of clonidine, al-
though, after a clinically relevant drop in blood pressure in
one participant, the final seven participants were given the
clonidine dose that was used by Nieuwenhuis et al. (2007).
Like Nieuwenhuis et al. (2007), we found no effect of cloni-
dine on the attentional blink, which poses a challenge for the
attentional blink theory of Nieuwenhuis et al. (2005b) under
the assumption that clonidine affects the phasic LC response.
However, the evidence that addresses this assumption is lim-
ited. As in the present study, clonidine has been found to
attenuate the amplitude of the P3 (Joseph and Sitaram 1989),
which has been proposed to reflect phasic LC activity
(Nieuwenhuis et al. 2005a). Furthermore, the suppressive
effect of clonidine on tonic LC activity (e.g., Abercrombie
and Jacobs 1987; Adams and Foote 1988), along with the
reported interaction between tonic and phasic activity of the
LC (Aston-Jones and Cohen 2005), suggests that clonidine
may also affect sensory-evoked LC responses. However, the
only study that we are aware of that directly examined this
issue foundmixed results: Adams and Foote (1988) found that
during the onset of clonidine-induced suppressed LC firing,
LC responses to sensory (footshock) stimuli were relatively
preserved, although later during the experiment, the reliability
of sensory-evoked LC responses was greatly reduced.
Furthermore, in another experiment conducted as part of this
study, we failed to find evidence that clonidine modulated the
phasic alerting response to a task-irrelevant, auditory
(Baccessory^) stimulus, despite it having an effect on general
alertness (Brown et al. 2015a). Thus, we may not have found
an effect of clonidine on the attentional blink because it is
possible that phasic LC responses to RSVP targets were
preserved.
Alternatively, if clonidine affects the phasic LC response,
as the observed reduction in T1-evoked P3 amplitude might
indicate, the theory of Nieuwenhuis et al. (2005b) could be
incorrect. For example, the size and the duration of the LC
refractory period, which is purportedly mirrored in the
attentional blink, may not be proportional to the size of the
phasic LC response, as the theory suggests, or noradrenaline
may not be involved in the attentional blink at all. At first
sight, the study by de Martino et al. (2008) suggests a role
of the noradrenergic system in the attentional blink: These
authors found that administration of the β-adrenoceptor an-
tagonist propranolol decreased T2 accuracy, while administra-
tion of the noradrenergic reuptake inhibitor reboxetine in-
creased accuracy for emotional T2 stimuli. However, the au-
thors found no interactions between lag and treatment, and in
one of their experiments, propranolol impaired T1 accuracy as
well. Taken together, these findings suggest that propranolol
and reboxetine do not specifically modulate the attentional
blink but target detection under RSVP conditions in general.
More convincing evidence for noradrenergic modulation of
the attentional blink was provided by Jepma et al. (2011),
who studied patients with dopamine-β-hydroxylase deficien-
cy, a rare genetic syndrome characterized by the complete lack
of noradrenaline. They found that these patients had a larger
attentional blink than healthy controls and that this impair-
ment was restored by treatment with a synthetic precursor
for noradrenaline. Although these findings pose a challenge
for the theory of Nieuwenhuis et al. (2005a), which explains
the attentional blink as a by-product of phasic noradrenaline
release in the LC, they are generally consistent with a role for
noradrenaline in the attentional blink. Recent studies have also
reported evidence that decreased levels of dopamine in the
striatum are associated with a larger attentional blink
(Colzato et al. 2011; Colzato et al. 2008; Slagter et al. 2012).
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Other neurotransmitters may hence also play a role in the
attentional blink.
In our study, clonidine had a clear detrimental effect on T1
identification accuracy. Presumably, clonidine impaired per-
formance by reducing general alertness (e.g., Brown et al.
2015a; Coull et al. 1997; Coull 2001; Smith and Nutt 1996),
a possibility that is supported by the negative effects of cloni-
dine on simple reaction time, and the fact that scopolamine,
which also increased simple reaction time, similarly reduced
T1 identification accuracy. Nieuwenhuis et al. (2007) did not
find a significant effect of clonidine on T1 accuracy. However,
in their study, all participants took the lower clonidine dose,
and their effect was in the same direction and of a similar
magnitude (5 %) as the effect we observed here (6 %). To
further understand the effect of clonidine on T1 accuracy, we
examined T1-related ERP waveforms (Kenemans and
Kähkönen 2011).
Clonidine attenuated the amplitude of the T1-evoked P2
and P3 components. The functional significance of the P2 is
relatively ill-defined, but it has been related to some aspect of
stimulus classification (reviewed in Key et al. 2005). The op-
posite seems to apply for the P3: Since its discovery in 1965, a
number of theories have been proposed to account for its
functional significance. In the context of the current paper,
the work by Nieuwenhuis et al. (2005a) is particularly rele-
vant, as these authors conceptualized the P3 as reflecting pha-
sic noradrenergic activity and the concomitant increase in neu-
ral gain. As noted above, the clonidine-related decrease in P3
amplitude is consistent with several previous studies
(Nieuwenhuis et al. 2005a; Joseph and Sitaram 1989). In con-
trast, previous studies have reported no effect of clonidine on
the amplitude of the P2 (Abuljawad et al. 2001; Turetsky and
Fein 2002). We propose that the effects of clonidine on T1-
evoked P2 and P3 amplitudes and corresponding behaviors
were mediated by a general decrease in alertness.
If clonidine reduced general alertness, why is that not man-
ifested in reduced overall T2 accuracy? Relatedly, why did
clonidine reduce lag-1 sparing? We propose that the percep-
tion of T1 caused a phasic alerting response that temporarily
compensated for the drug-induced decrease in tonic alertness.
As we have shown in other work, drug-related reductions in
alertness yield room for compensatory accessory stimulus-
induced performance improvements (Brown et al. 2015a). In
a similar vein, Smith and Nutt (1996) found that arousal
evoked by white noise can reduce the frequency of attentional
lapses induced by clonidine intake. Furthermore, we propose
that this phasic alerting response takes some time to unfold.
This is suggested by our finding that the drug-related impair-
ments in T1 accuracy extended to T2 accuracy if T2 was
presented immediately after T1 (i.e., at lag 1). Only after that,
from lag 2 onward, did accuracy return to placebo levels.
The scopolamine findings show a remarkable similarity to
the clonidine findings. Like clonidine, scopolamine reduced
T1 accuracy without having a clear effect on T2 accuracy. The
reduction in T1 accuracy is generally consistent with a number
of studies that have reported scopolamine-induced attentional
impairments, as indicated by impaired performance in
sustained attention tasks (Hasselmo and Sarter 2011).
Scopolamine also led to reduced amplitudes of the P2 and
P3 relative to placebo, although these reductions were not
statistically significant.
It is possible that the effects of clonidine and scopolamine
on behavior and ERP waveforms, though similar, were
achieved via largely independent neural pathways that both
affect general alertness. However, we believe that it is more
plausible that the similar effects of these two drugs in the
current study and another recent study in our lab (Brown
et al. 2015a) reflect interactions between the two
neuromodulator systems involved (Briand et al. 2007). On
one hand, acetylcholine has been demonstrated to activate
LC neurons in rats and co-administration of scopolamine re-
duces this effect (Egan and North 1985; Adams and Foote
1988). Egan and North proposed that scopolamine antago-
nizes muscarinic receptors in the LC, leading to reduced nor-
adrenergic baseline activation. On that assumption, both clo-
nidine and scopolamine may have reduced noradrenergic
baseline activity, leading to a similar pattern of results for both
treatments. On the other hand, there is solid evidence that
clonidine inhibits cortical ACh release (Acquas et al. 1998),
probably via α2 receptors in the basal forebrain (cf.
Dringenberg and Vanderwolf 1998). This suggests that both
clonidine and scopolamine may have reduced basal forebrain
activity and consequent release of acetylcholine, thus leading
to a similar pattern of results. The current data underline the
importance of studying interactions between the noradrener-
gic and cholinergic neuromodulator systems in regulating
temporal fluctuations in attention.
Some limitations of this study are worth mentioning. First,
a general disadvantage of a within-subject design is that it is
sensitive to practice effects. In our experiment, participants
also became better at the task over the course of the three
sessions. T2 accuracy increased with session, but this effect
was not limited to the attentional blink; it occurred for all lags
(cf. Slagter et al. 2007). This general practice effect likely
contributed to increased error variance—T2 accuracy differ-
ences between sessions that were not due to treatment—de-
creasing the power to detect an existing effect. However, treat-
ment was counterbalanced across sessions, and we found no
effect of treatment order, suggesting that practice did not in-
teract with treatment. Practice effects thus cannot easily ac-
count for the null effect of treatment on attentional blink mag-
nitude and, more generally, T2 performance. A second poten-
tial limitation of our study is that the majority (15/18) of the
participants were women and that the menstrual cycle was not
taken into account and use of contraceptives was not regis-
tered. We are not aware of studies that have reported
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systematic performance differences in RSVP tasks as a func-
tion of sex, menstrual cycle, or use of contraceptives (but see
Holländer et al. 2005), but we cannot exclude the possibility
of such effects in our study.
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